Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators ...

Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.25 per share, versus a year-ago ...

The RMR Group (Nasdaq: RMR) today announced on behalf of its managed joint venture that it has facilitated a $1.0 billion five-year, interest-only fixed rate mortgage financing with a weighted-average ...

Some Boston public school students are spending their summer vacations learning and working at a global biotech company.

Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint – ...

Valued at a market cap of $117.7 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company that ...

For the third summer in a row, Vertex Pharmaceuticals brought its commitment to community and STEM education to life through hands-on science experiments led by its high school interns for local youth ...

The list, released by Fortune for only the second time, recognises individuals who are not only active in business but also ...

BOSTON (AP) — BOSTON (AP) — Vertex Pharmaceuticals Inc. (VRTX) on Monday reported second-quarter profit of $1.03 billion. The Boston-based company said it had net income of $3.99 per share. Earnings, ...

BOLD TYPES Josh and Amy Boger give $1 million to close out Boston Arts Academy’s $35 million campaign The former Vertex CEO and his wife have long been supporters of the city arts school ...

expand Jeffrey Leiden, President and CEO, Vertex Pharmaceuticals Jon Chomitz By Don Seiffert – Managing Editor, Boston Business Journal Apr 30, 2015 Updated Apr 30, 2015 3:01pm EDT ...

Developer Joseph Fallon, Boston Mayor Thomas M. Menino and a crowd of construction workers watched Thursday as the final beam for the first of two Vertex Pharmaceuticals (Nasdaq: VRTX) office ...